Role of astrocyte μ-δ opioid receptor heterodimer in treatment of depression-associated diseases
By increasing the abundance and activity of μ-δ opioid receptor heterodimers in astrocytes, and using μ-δ opioid receptor heterodimer agonists to treat major depressive disorder, this approach addresses the issues of slow efficacy and significant side effects associated with existing drugs, providing a rapid and effective treatment option for depression.
Patent Information
- Application Number
- PCT/CN2026/097603
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Existing treatments for major depressive disorder, such as SSRIs and SNRIs, take several weeks to show effects, and about 30%-40% of patients do not respond to these drugs and develop treatment-resistant depression. Furthermore, existing drugs such as ketamine have side effects and addiction problems.
We developed astrocyte μ-δ opioid receptor heterodimers and their agonists to enhance the abundance and activity of μ-δ opioid receptor heterodimers for the preparation of pharmaceutical compositions to treat depression-related, anxiety-related, and pain-related disorders. Agonists such as (2R,6R)-hydroxynorketamine (HNK) bind to μ-δ opioid receptor heterodimers, enhancing excitatory synaptic transmission and upregulating GLT-1 expression levels.
It rapidly and effectively improves depressive symptoms, reduces side effects, provides a treatment option for treatment-resistant depression, enhances excitatory synaptic transmission and improves behavioral hopelessness, increases GluA1 levels, and improves anhedonia.
Smart Images

Figure PCTCN2026097603-FTAPPB-I100001 
Figure PCTCN2026097603-FTAPPB-I100002 
Figure PCTCN2026097603-FTAPPB-I100003
Abstract
Description
The role of astrocyte μ-δ opioid receptor heterodimers in the treatment of depression-related disorders Technical Field
[0001] This invention relates to the field of biomedicine, specifically to the role of astrocyte μ-δ opioid receptor heterodimers in the treatment of depression-related diseases. Background Technology
[0002] Major depressive disorder (MDD) is a common mental illness affecting hundreds of millions of people worldwide and is a leading cause of disability and premature death. Currently, both pharmacological and non-pharmacological interventions for MDD are far from satisfactory. First-line treatments, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), typically take several weeks to show therapeutic effects. Furthermore, approximately 30%–40% of patients with MDD do not respond to these medications, progressing to treatment-resistant depression (TRD).
[0003] The discovery of racemic (R,S)-ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, for its rapid and sustained antidepressant effects has brought hope to patients with treatment-resistant depression. Dextro-ketamine (S-ketamine) has been approved by the U.S. Food and Drug Administration, becoming the first non-monoamine antidepressant in recent decades. However, ketamine's psychogenic side effects and potential addictiveness severely hinder its clinical application and widespread use.
[0004] Therefore, there is an urgent need in this field to develop a new drug for treating depression-related diseases that has low side effects and is non-addictive. Summary of the Invention
[0005] The purpose of this invention is to provide information on the role and application of astrocyte μ-δ opioid receptor heterodimers and their agonists in antidepressant-like diseases.
[0006] In a first aspect of the invention, there is provided the use of a μ-δ opioid receptor heterodimer or an agonist thereof for the preparation of a pharmaceutical composition for the treatment of depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0007] In another preferred embodiment, the μ-δ opioid receptor heterodimer is a μ-δ opioid receptor heterodimer found in astrocytes.
[0008] In another preferred embodiment, the μ-δ opioid receptor heterodimer agonist is used to increase the abundance and / or activity of the μ-δ opioid receptor heterodimer.
[0009] In another preferred embodiment, the enhancement of the abundance of μ-δ opioid receptor heterodimers includes: increasing the number of μ-δ opioid receptor heterodimers or promoting the formation of μ-δ opioid receptor heterodimers.
[0010] In another preferred embodiment, enhancing the activity of the μ-δ opioid receptor heterodimer includes: activating the μ-δ opioid receptor heterodimer, increasing the activation level of the μ-δ opioid receptor heterodimer structure, or enhancing the stability of the μ-δ opioid receptor heterodimer structure.
[0011] In another preferred embodiment, the agonist is selected from the group consisting of small molecule compounds, proteins, nucleic acids, or combinations thereof.
[0012] In another preferred embodiment, the agonist binds to a μ-δ opioid receptor heterodimer.
[0013] In another preferred embodiment, the agonist binds to key sites of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, said key sites including: D147, Y148, V300, or combinations thereof (numbered based on the sequence of the mouse μ-opioid receptor).
[0014] In another preferred embodiment, the binding of the agonist to the μ-δ opioid receptor heterodimer involves the following intermolecular forces: salt bridge interaction with D147 and / or π-π stacking interaction with Y148.
[0015] In another preferred embodiment, the agonist comprises (2R,6R)-hydroxydemethylketamine (HNK) or CYM51010.
[0016] In another preferred embodiment, the agonist has one or more activities selected from the group consisting of:
[0017] (1) Enhances excitatory synaptic transmission in subjects;
[0018] (2) Increase the amount of GluA1 in the subjects;
[0019] (3) Upregulates GLT-1 expression levels in astrocytes;
[0020] (4) Improved behavioral despair in subjects;
[0021] (5) Improves the subject's lack of pleasure.
[0022] In another preferred embodiment, the disorder or condition includes: depression, anxiety, pain, or a combination thereof.
[0023] In another preferred embodiment, the disorder or condition is depression, preferably major depressive disorder or treatment-resistant depression.
[0024] In another preferred embodiment, the pharmaceutical composition is administered to subjects who have the following subtype characteristics: the abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes are lower than those of normal controls.
[0025] In another preferred embodiment, the normal control is a healthy individual of the same species as the subject who does not suffer from depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0026] In another preferred embodiment, the abundance A1 of μ-δ opioid receptor heterodimers in the subject's astrocytes is A1 / A0 ≤ 0.9, preferably ≤ 0.8, and more preferably ≤ 0.5, compared to the abundance A0 of μ-δ opioid receptor heterodimers in the astrocytes of a normal control.
[0027] In another preferred embodiment, the activity B1 of the μ-δ opioid receptor heterodimer in the subject's astrocytes is B1 / B0 ≤ 0.9, preferably ≤ 0.8, and more preferably ≤ 0.5, compared to the activity B0 of the μ-δ opioid receptor heterodimer in the astrocytes of a normal control.
[0028] In another preferred embodiment, the abundance and / or activity of the μ-δ opioid receptor heterodimer in the astrocytes is measured by detecting the binding level of the μ-opioid receptor ligand.
[0029] In another preferred embodiment, the subjects include mammals, such as humans, non-human primates, rodents (such as mice, rats), etc.
[0030] In a second aspect of the invention, a pharmaceutical composition is provided, the pharmaceutical composition comprising:
[0031] (i) A therapeutically effective dose of a μ-δ opioid receptor heterodimer agonist; and
[0032] (ii) Pharmaceutically acceptable carriers.
[0033] In another preferred embodiment, the pharmaceutical composition includes: injection, tablet, powder, granule, capsule, lyophilized preparation, solution, and syrup.
[0034] In another preferred embodiment, the pharmaceutically acceptable carrier includes, but is not limited to: solvents, dispersion media, coatings, antibacterial or antifungal agents, isotonic agents and absorption delay agents, buffered saline, physiological saline, phosphate buffer, citrate buffer, acetate buffer, bicarbonate buffer, sucrose solution, salt solution, polysorbate solution, or combinations thereof.
[0035] In another preferred embodiment, the pharmaceutically acceptable carrier is a delivery carrier, including but not limited to liposomes, nanoparticles, etc.
[0036] In another preferred embodiment, the pharmaceutical composition further comprises:
[0037] (iii) Other active substances for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0038] In another preferred embodiment, the other active substances for treating depression-related, anxiety-related, and / or pain-related disorders or conditions include: selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs).
[0039] In a third aspect of the invention, a medicine box is provided, the medicine box comprising:
[0040] (a) a first pharmaceutical composition, said first pharmaceutical composition comprising (a1) a μ-δ opioid receptor heterodimer agonist; and (a2) a pharmaceutically acceptable carrier; and
[0041] (b) A second pharmaceutical composition comprising (b1) another medicine for treating depression-related, anxiety-related, and / or pain-related disorders or conditions; and (a2) a pharmaceutically acceptable carrier.
[0042] In another preferred embodiment, the first drug and the second drug are independent of each other.
[0043] In another preferred embodiment, other medications for treating depression-related, anxiety-related, and / or pain-related disorders or conditions include: monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), SSRIs, SNRIs, and tetracyclic antidepressants such as maprotiline.
[0044] In a fourth aspect of the invention, a kit is provided, the kit comprising:
[0045] (Y1) Detection reagent, wherein the detection reagent is a reagent for detecting the abundance and / or activity of μ-δ opioid receptor heterodimers; and
[0046] (Y2)μ-δ opioid receptor heterodimer agonist.
[0047] In another preferred embodiment, the detection reagent is used to detect the abundance and / or activity of μ-δ opioid receptor heterodimers in the test subject.
[0048] In another preferred embodiment, the kit further includes a label and / or instructions.
[0049] In another preferred embodiment, the label and / or instructions describe the method of administration of the kit: using the (Y1) test reagent to detect whether the abundance and / or activity of μ-δ opioid receptor heterodimer in the subject is lower than that in the normal control; if so, administering the (Y2) μ-δ opioid receptor heterodimer agonist to the subject.
[0050] In another preferred embodiment, the μ-δ opioid receptor heterodimer is a μ-δ opioid receptor heterodimer found in astrocytes.
[0051] In another preferred embodiment, the μ-δ opioid receptor heterodimer agonist is as described above.
[0052] In another preferred embodiment, the agonist binds to key sites of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, said key sites including: D147, Y148, V300, or combinations thereof (numbered based on the sequence of the mouse μ-opioid receptor).
[0053] In another preferred embodiment, the binding of the agonist to the μ-δ opioid receptor heterodimer involves the following intermolecular forces: salt bridge interaction with D147 and / or π-π stacking interaction with Y148.
[0054] In another preferred embodiment, the agonist comprises (2R,6R)-hydroxydemethylketamine (HNK) or CYM51010.
[0055] In a fifth aspect of the invention, a method is provided for screening or identifying potential therapeutic agents for treating depression-related, anxiety-related, and / or pain-related disorders or conditions, the method comprising the steps of:
[0056] (S1) In the test group, the test substance was added to the cell culture system, and the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the cells of the test group were observed; in the control group, the test compound was not added to the same cell culture system, and the abundance (A0) and / or activity (B0) of μ-δ opioid receptor heterodimers in the cells of the control group were observed.
[0057] If the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the test group are significantly higher than those in the control group, it indicates that the test substance is a potential therapeutic agent for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0058] In another preferred embodiment, the method further includes step (S2): applying the candidate substance identified in step (S1) to animal models of depression-related, anxiety-related, and / or pain-related conditions, and measuring its effects on the animals to determine its therapeutic efficacy.
[0059] In another preferred embodiment, "significantly higher than" means A1 / A0 ≥ 1.2, more preferably, A1 / A0 ≥ 1.5, and even more preferably, A1 / A0 ≥ 2.
[0060] In another preferred embodiment, “significantly higher than” means E1 / E0 ≥ 1.2, more preferably, E1 / E0 ≥ 1.5, and even more preferably, E1 / E0 ≥ 2.
[0061] In another preferred embodiment, the cells comprise astrocytes.
[0062] In another preferred embodiment, the cells are astrocytes cultured in vitro.
[0063] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
[0064] In a sixth aspect of the invention, a method is provided for screening or identifying small molecule compounds for treating depression-related, anxiety-related, and / or pain-related disorders or conditions, the method comprising the steps of:
[0065] (Z1) Provides a test compound and predicts or detects whether the test compound binds to a μ-δ opioid receptor heterodimer; if the test compound binds to a μ-δ opioid receptor heterodimer, it indicates that the test compound is a candidate compound for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0066] In another preferred embodiment, the test compound is predicted or detected to bind to a key site of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, the key site including: D147, Y148, V300, or a combination thereof.
[0067] In another preferred embodiment, the bonding includes forming forces that interact with the salt bridge of D147 and / or with the π-π stacking of Y148.
[0068] In another preferred embodiment, the prediction includes: using computational simulation tools or software to predict whether the test compound binds to the μ-δ opioid receptor heterodimer.
[0069] In another preferred embodiment, the method further includes step (Z2): administering the candidate compound identified in step (Z1) to animal models of depression-related, anxiety-related, and / or pain-related conditions, and measuring its effects on the animals to determine its therapeutic efficacy.
[0070] In a seventh aspect of the invention, a method for treating depression-related, anxiety-related, and / or pain-related disorders or conditions is provided, the method comprising: administering a μ-δ opioid receptor heterodimer agonist to a subject in need.
[0071] In another preferred embodiment, the object includes a human or a non-human mammal.
[0072] In another preferred embodiment, the subject is a patient suffering from a depression-related, anxiety-related, and / or pain-related disorder or condition.
[0073] In another preferred embodiment, the subject is a subject with the following subtyping characteristics: the abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes are lower than those of normal controls.
[0074] In an eighth aspect of the invention, there is provided the use of a small molecule compound in the preparation of an agonist for increasing the abundance and / or activity of a μ-δ opioid receptor heterodimer, said small molecule compound binding to a key site of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, said key site including: D147, Y148, V300, or combinations thereof (numbered based on the sequence of the mouse μ-opioid receptor).
[0075] In another preferred embodiment, the binding of the small molecule compound to the μ-δ opioid receptor heterodimer involves the following intermolecular forces: salt bridge interaction with D147 and / or π-π stacking interaction with Y148.
[0076] In another preferred embodiment, the small molecule compound includes: (2R,6R)-hydroxydemethylketamine (HNK) and CYM51010.
[0077] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description
[0078] Figure 1 shows that the enhanced excitatory synaptic transmission induced by ketamine and hydroxynorketamine (HNK) involves different mechanisms.
[0079] A. In acutely prepared hippocampal slices, ketamine increased the slope of the excitatory postsynaptic potential (fEPSP) in the CA1 radicular region induced by the Scheffer collateral (SC). The left side shows the time curve of the SC-CA1 fEPSP slope; the right side shows representative fEPSP recordings before, after, and after ketamine administration combined with HNK.
[0080] B. After 10 μM ketamine induced an increase in SC-CA1 fEPSP and reached a plateau, increasing the ketamine concentration to 30 μM did not cause further enhancement of SC-CA1 fEPSP.
[0081] C.MK-801, a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, mimics the effect of ketamine in enhancing SC-CA1 fEPSP without inhibiting the action of HNK.
[0082] D and G. DAMGO, a selective μ-opioid receptor (MOR) agonist, increased the upward slope of SC-CA1 fEPSP and blocked the effect of HNK on SC-CA1 fEPSP, while ketamine further enhanced SC-CA1 fEPSP on the basis of the effect of DAMGO.
[0083] E and H. The selective MOR antagonist CTOP significantly reduced the upward slope of SC-CA1 fEPSP and blocked the effect of HNK, but had no effect on the effect of ketamine.
[0084] F and I. In the presence of APV (a selective and competitive NMDA receptor antagonist), CTOP completely blocked the enhancing effect of ketamine on SC-CA1 fEPSP.
[0085] Data in A comes from 7 brain slices from 7 mice, data in B comes from 9 brain slices from 8 mice, and data in C comes from 17 brain slices from 12 mice. The points in G, H, and I represent the number of brain slices used to obtain fEPSP in D, E, and F. Scale bar in AC: 5 ms, 0.2 mV.
[0086] Figure 2 shows that the absence of MOR or DOR opioid receptors in astrocytes can eliminate the antidepressant-like effect of (2R,6R)-HNK.
[0087] A. In the forced swimming test (FST), intraperitoneal injection (ip) of 10 mg / kg DAMGO mimicked the effect of HNK in reducing immobility time in mice, while intraventricular injection (icv) of 3 μg / kg CTOP reversed this effect.
[0088] B. In the sucrose preference test (SPT), DAMGO mimicked the effect of HNK in increasing sucrose preference in mice, while CTOP reversed this effect.
[0089] C. In the three-compartment social interaction test, injection of HNK or DAMGO increased the time spent by mice interacting with unfamiliar mice during the social novelty test phase (single-stranger phase, left image). Mice injected with HNK or DAMGO also spent more time interacting with new unfamiliar mice during the social novelty test phase (double-stranger phase, right image). Intraventricular injection of 3 μg / kg CTOP completely reversed the effects of HNK in both phases.
[0090] D and E. Compared with wild-type littermate control mice, MOR knockout mice exhibited depressive-like behavior in FST (increased immobility time, D) and reduced sucrose solution intake in SPT (E).
[0091] Intraperitoneal injection of 10 mg / kg HNK had no effect on immobility time in MOR knockout mice in FST (F) and also did not alter their sucrose solution intake in SPT (G).
[0092] H and I. MOR-specific loss in astrocytes (OPRM1) GFAP -cKO) can block the antidepressant-like effects of HNK in FST and SPT. In contrast, HNK can reduce OPRM1 flox / flox The immobility time of mice in the FST was reduced, and their sucrose intake was increased.
[0093] J. 10 μM HNK can enhance acutely prepared OPRM1 flox / flox Excitatory postsynaptic potentials (fEPSPs) of SC-CA1 in mouse brain slices, but not of OPRM1. GFAP -cKO mouse brain slices did not have this effect.
[0094] K. 10 μM HNK can increase acutely prepared OPRM1 flox / flox The content of GluA1 in mouse hippocampal brain slices, but not on OPRM1. GFAP -cKO mouse brain slices did not have this effect.
[0095] L and M.HNK at OPRD1 flox / flox In control mice, both FST (reduced immobility time, L) and SPT (increased sucrose solution intake, M) showed antidepressant-like effects, but in mice with astrocyte-specific loss of δ-opioid receptors (OPRD1)... GFAP This effect was not observed in -cKO mice.
[0096] N.HNK can enhance OPRD flox / flox SC-CA1 fEPSP in control mice, but not for OPRD1 GFAP -cKO mice did not have this effect.
[0097] O.HNK can increase the acute preparation of OPRD1 flox / flox The content of GluA1 in the hippocampus of mice was compared with that of OPRD1. GFAP -cKO mouse brain slices did not have this effect.
[0098] P and Q. Representative Western blot analysis (P) and data summary (Q) showed that incubation with 10 μM HNK for 2 hours increased the levels of brain-derived neurotrophic factor (BDNF) in hippocampal astrocyte cultures and hippocampal neuron-astrocytocyte co-cultures, but had no effect on hippocampal neuron cultures; HNK incubation also increased the levels of GluA1 in hippocampal neuron-astrocytocyte co-cultures, but had no effect on neuron or astrocyte cultures alone.
[0099] Examples of immunofluorescence images of primary hippocampal neuron cultures before and after incubation with 10 μM HNK for 2 hours in the absence of (R) or in the presence of (S) astrocytes, showing punctate markings (green) of GluA1 (red) on the cell membrane surface and neuronal nuclear antigen (NeuN) at the cell body and proximal processes; Horizontal image: Enlarged view of the selected portion of the GluA1 image (white box). Scale bar: 10 μm.
[0100] T. Quantitative analysis of the number and size of GluA1 clusters in R and S. Each point represents an independent experiment.
[0101] Figure 3 shows that activation of the MOR-DOR heterodimer mimics the antidepressant-like effect of (2R,6R)-HNK, while selective blockade of these receptors eliminates such effects.
[0102] A. 1 μM of DPDPE (an opioid receptor agonist containing DOR) failed to enhance OPRM1. GFAP -cKO mouse brain slices showed excitatory field postsynaptic potentials (fEPSPs) of SC-CA1, but significantly enhanced OPRM1. flox / flox SC-CA1 fEPSP in control mouse brain slices.
[0103] B. 1 μM DAMGO did not enhance SC-CA1fEPSP in brain slices of OPRD1GFAP-cKO mice, but it significantly enhanced OPRD1 flox / flox SC-CA1 fEPSP in control mouse brain slices.
[0104] C.50 nM CYM51010 (CYM, a selective MOR-DOR heterodimer agonist) mimics the effect of HNK enhancing SC-CA1 fEPSP, and this effect overlaps with that of HNK (i.e., HNK no longer has an additional enhancing effect when CYM is used).
[0105] The D.1 μM selective MOR-DOR blocking peptide completely blocked the effect of HNK on SC-CA1 fEPSP.
[0106] E.50 nM CYM mimics the effect of HNK-induced acute preparation of increased GluA1 content in hippocampal slices, and this effect overlaps with that of HNK.
[0107] F.1 μM of the MOR-DOR blocking peptide eliminated the effect of HNK-induced increase in GluA1 content in acutely prepared hippocampal slices.
[0108] In mice treated with corticosteroids for 3 weeks (with 1 μM corticosteroids added to drinking water) for three weeks, intraperitoneal injection of 4 mg / kg CYM mimicked the antidepressant-like effect of intraperitoneal injection of 10 mg / kg HNK, and this effect overlapped with that of HNK; while intraventricular injection of 2 μg / 300 nL of MOR / DOR blocking peptide (PEP) eliminated the antidepressant-like effect of HNK in both tests.
[0109] I. In the forced swimming test, intraperitoneal injection of 4 mg / kg CYM mimicked the HNK-induced reduction in immobility time in mice treated with 3 weeks of corticosteroids, and this effect overlapped with that of HNK; while intraventricular injection of 2 μg / 300 nL PEP eliminated the antidepressant effect of HNK in this test.
[0110] J. In the tail suspension test, intraperitoneal injection of 4 mg / kg CYM mimicked the HNK-induced reduction in immobility time in mice treated with corticosteroids for 3 weeks, and this effect overlapped with that of HNK; while intraventricular injection of 2 μg / 300 nL PEP eliminated the antidepressant effect of HNK in this test.
[0111] Figure 4 shows that (2R,6R)-HNK increases the abundance of μ-δ heterodimers.
[0112] A. Representative immunofluorescence images of μ-δ heterodimer (red), GFAP (astrocytocyte marker, green), and DAPI (nucleus, blue) in hippocampal slices from wild-type control mice (left), CUMS mice (middle), and CUMS mice treated with 1 hour (2R, 6R)-HNK (10 mg / kg, intraperitoneal injection, right). Scale bar: 25 μm.
[0113] B. Quantitative analysis of the number of μ-δ heterodimers (red spots) per square millimeter.
[0114] C. Quantitative analysis of the number of μ-δ heterodimers (red spots) in each astrocyte.
[0115] Example images of D.MINFLUX tracking MOR (red) and DOR (green) expression in CHO cells, with treatment groups including saline (control), CYM51010 (50 nM), (2R,6R)-HNK (10 μM), PEP (1 μM), PEP+CYM51010, and PEP+(2R,6R)-HNK.
[0116] E. A summary of data from six independent MINFLUX imaging experiments, tracing the distance between MOR and DOR in CHO cells of the above-mentioned treatment groups.
[0117] F and G. Probability distribution of the distance between MOR and DOR in CHO cells of each treatment group (treatment group same as E).
[0118] The binding mechanism of HJ(2R,6R)-HNK to the μ-δ opioid receptor heterodimer complex. The amino acid residues (I) in contact with (2R,6R)-HNK within the binding pocket are highlighted on the right. The binding affinity (J) of each residue to (2R,6R)-HNK was calculated using the last 100 ns of simulated data via the MMPBSA method.
[0119] Example image of the effect of (2R,6R)-HNK on YFP fluorescence levels in a bimolecular fluorescence complementation (BiFC) assay (OPRM and OPRD coding sequences were cloned into the N-terminal and C-terminal fragments of Mvenus YFP, respectively, and expressed in HEK293T cells). Left: wild type; Right: OPRM N-terminal (2R,6R)-HNK binding pocket amino acid residue mutated to alanine.
[0120] The time course of fluorescence level changes in Mvenus YFP constructed before and after L.(2R,6R)-HNK perfusion. Mutations in the 147 domain include D147A, Y148A, M151A, and F152A; mutations in the 236 domain include V236A and F237A; mutations in the 293 domain include W293A, I293A, H293A, and V300A; the MOR mutant contains all of the above mutations.
[0121] Figure 5 shows that HNK-induced elevation of GLT-1 levels reduces environmental NMDAR response and mediates antidepressant effects.
[0122] A. Microdialysis assay to detect the effect of HNK injection on extracellular glutamate ([Glu]e) concentration in PrL cells.
[0123] Example waveforms (left) and quantification results (right) of the NMDAR response in the B.PrL excitatory neuronal environment. The ACTH mouse response was enhanced and recovered after HNK injection.
[0124] C. Example waveforms (left) and response quantification (right) of synaptic NMDAR EPSC in wild-type mice, ACTH+saline, and ACTH+HNK mice before and after 20 μM DL-TBOA perfusion.
[0125] Dose-response curves of D.HNK levels on GLT-1 (left) and BDNF (right) levels in CTX TNA2 cells.
[0126] CTX TNA2 cell GLT-1 protein levels 1 hour after E.HNK or APV treatment.
[0127] The effect of F.GLT-1 knockdown virus on GLT-1 protein levels in the brain.
[0128] The environmental NMDAR response of PrL excitatory neurons in mice knocked down by G.GLT-1 or injected with the control virus was reduced.
[0129] H.GLT-1 knockdown of the effect of HNK on the frequency and amplitude of sEPSC in PrL excitatory neurons of mice.
[0130] I. After injecting GLT-1 into the PFC and hippocampus to knock down the virus, the effect of HNK on FST (left) and SPT (right) disappeared.
[0131] J. Mechanism diagram. Detailed Implementation
[0132] Through extensive and in-depth research, the inventors, by elucidating the antidepressant mechanism of ketamine metabolite (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), have for the first time revealed the important role of μ-δ opioid receptor heterodimers in antidepressant activity. Specifically, upregulation of the number and / or activity of μ-δ opioid receptor heterodimers in astrocytes can exert an antidepressant effect. Based on this, novel antidepressant targets and methods targeting μ-δ opioid receptor heterodimers are provided. This invention also provides the use of μ-δ opioid receptor heterodimer agonists in the treatment of depression-related, anxiety-related, and / or pain-related diseases, and provides corresponding pharmaceutical compositions, treatment methods, and drug screening methods. This invention was completed based on these findings.
[0133] definition
[0134] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0135] As used herein, when referring to a specific enumerated value, the term “about” means that the value can vary by no more than 1% from the enumerated values. For example, as used herein, the expression “about 100” includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0136] As used herein, the terms “containing” or “including (comprise)” can be open-ended, semi-closed, or closed. In other words, the terms also include “consistently made of” or “composed of”.
[0137] As used in this paper, the data processing and analysis methods are routinely applicable to those skilled in the art. *P<0.05; **P<0.01; ***P<0.001; ns, no significant difference; analysis of variance (ANOVA) was performed followed by Hildak analysis. Multiple comparison tests. Data are expressed as mean ± standard error (SEM).
[0138] μ-δ opioid receptor heterodimer
[0139] Opioid receptors (ORs) are a class of G protein-coupled receptors (GPCRs), including μ-opioid receptors (MORs), delta-opioid receptors (DORs), κ-opioid receptors (KORs), and nociceptive opioid receptors (NOPRs). Opioid receptors are widely distributed in the central nervous system and peripheral tissues, participating in the regulation of various physiological processes such as pain, mood, reward, respiration, and gastrointestinal function. Opioid drugs (such as morphine and fentanyl) exert their analgesic and other effects by activating these opioid receptors.
[0140] As used in this article, the term "μ-opioid receptor" is also abbreviated as MOR. The μ-opioid receptor (mouse-derived) is located in the NCBI sequence as follows:
[0141] Known μ-opioid receptor selective agonists include DAMGO, and μ-opioid receptor selective antagonists include CTOP.
[0142] As used in this article, the term "δ-opioid receptor" is also abbreviated as DOR. The sequence of the δ-opioid receptor (mouse-derived) is as follows:
[0143] Known δ-opioid receptor selective agonists include DPDPE, and δ-opioid receptor selective antagonists include ICI174684.
[0144] In this invention, μ-opioid receptors / δ-opioid receptors include human μ-opioid receptors / δ-opioid receptors, as well as μ-opioid receptors / δ-opioid receptors from non-human mammals, such as mice or rats.
[0145] Recent studies have found that opioid receptors not only exist in monomeric form, but can also form homodimers or heterodimers with other opioid receptors or non-opioid receptors (such as dopamine receptors and adrenaline receptors).
[0146] As used herein, the terms “μ-δ opioid receptor heterodimer,” “heterodimer of the present invention,” “heterodimer of the present invention,” and “MOR-DOR heterodimer” are used interchangeably and all refer to a functional complex formed by the interaction of μ-opioid receptors and δ-opioid receptors. The μ-δ opioid receptor heterodimer has been shown to exist both in vivo and in vitro.
[0147] In this invention, the role of μ-δ opioid receptor heterodimer in antidepressant effects was revealed for the first time through the study of the antidepressant-like mechanism of (2R,6R)-hydroxydemethylketamine ((2R,6R)-HNK).
[0148] Specifically, knockout of μ-opioid receptors or delta-opioid receptors in astrocytes, or administration of antagonists of μ-opioid receptors or delta-opioid receptors, can block the antidepressant-like effects of (2R,6R)-HNK. Increased abundance of μ-δ-opioid receptor heterodimers on astrocytes was detected in subjects administered (2R,6R)-HNK, and this effect can be mimicked by the μ-δ-opioid receptor heterodimer agonist CYM51010. In animal models with delta-opioid receptor knockout, administration of μ-opioid receptor agonists failed to produce an antidepressant-like effect; similarly, administration of delta-opioid receptor agonists also failed to produce an antidepressant-like effect. These results indicate that μ-δ-opioid receptor heterodimers in astrocytes play a crucial role in the antidepressant-like effect.
[0149] μ-δ opioid receptor heterodimer agonists
[0150] In this invention, the role of μ-δ opioid receptor heterodimer agonists in antidepressant-like effects is provided.
[0151] As used herein, the term "agonist" is used interchangeably with "promoter," "activator," "upregulator," etc. The terms "μ-δ opioid receptor heterodimer agonist" and "agonist of the present invention" are used interchangeably and refer to any substance that can increase the abundance or activity of μ-δ opioid receptor heterodimers.
[0152] As used herein, "increasing the abundance of μ-δ opioid receptor heterodimers" includes, but is not limited to, increasing the number of μ-δ opioid receptor heterodimers or promoting the formation of μ-δ opioid receptor heterodimers. Preferably, it refers to promoting the formation or increasing the number of μ-δ opioid receptor heterodimers on astrocytes, and more specifically, μ-δ opioid receptor heterodimers on the cell membrane of astrocytes.
[0153] As used herein, “enhancing the activity of μ-δ opioid receptor heterodimers” includes, but is not limited to: activating μ-δ opioid receptor heterodimers, increasing the activation level of μ-δ opioid receptor heterodimer structures, or enhancing the stability of μ-δ opioid receptor heterodimer structures. The term “activation” includes signal transduction that initiates signaling pathways associated with μ-δ opioid receptor heterodimers.
[0154] Preferably, the μ-δ opioid receptor heterodimer agonist increases the abundance (quantity) or activity (function) of μ-δ opioid receptor heterodimers by at least 20%, preferably at least 50%, and more preferably at least 80%.
[0155] In a preferred embodiment, the μ-δ opioid receptor heterodimer agonist comprises an agonist that specifically upregulates the abundance (quantity) or activity (function) of μ-δ opioid receptor heterodimers on the astrocyte cell membrane.
[0156] The type and variety of μ-δ opioid receptor heterodimer agonists of the present invention are not limited, and may be, for example, small molecule compounds, proteins, nucleic acids, or combinations thereof. The agonists of the present invention also include gene editing reagents. Exemplary μ-δ opioid receptor heterodimer agonists include (2R,6R)-hydroxydemethylketamine ((2R,6R)-HNK) and CYM51010.
[0157] Preclinical studies have shown that the ketamine metabolite (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) has similar antidepressant effects to ketamine without inducing significant psychomyopathic effects or addiction-related behaviors. At antidepressant doses, (2R,6R)-HNK does not inhibit NMDAR, exhibiting a different antidepressant mechanism from ketamine; however, the specific antidepressant mechanism of (2R,6R)-HNK remains to be elucidated.
[0158] In some embodiments, the agonist of the present invention exerts its effect by binding to a μ-δ opioid receptor heterodimer. In this invention, the structure of the μ-δ opioid receptor heterodimer is resolved for the first time, and the binding sites of the μ-δ opioid receptor heterodimer and the agonist are revealed. Exemplarily, (2R,6R)-HNK binds to key sites of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, said key sites including D147, Y148, V300, or combinations thereof, numbered based on the wild-type μ-opioid receptor sequence in mice. More specifically, the binding of the agonist to the μ-δ opioid receptor heterodimer involves the following intermolecular forces: a salt-bridge interaction with D147 and a π-π stacking interaction with Y148.
[0159] The μ-δ opioid receptor heterodimer agonist of the present invention has an antidepressant-like effect. As used herein, the terms “antidepressant-like effect” and “antidepressant-like response” are used interchangeably to refer to an effect similar to that of a known antidepressant, which can alleviate depressive-like behavior or improve depression-related neurobiological markers.
[0160] In a preferred embodiment, the antidepressant-like effect is manifested as one or more of the following activities:
[0161] (1) Enhances excitatory synaptic transmission in subjects;
[0162] (2) Increase the amount of GluA1 in the subjects;
[0163] (3) Improve subjects’ behavioral despair; and / or
[0164] (4) Improves the subject's lack of pleasure.
[0165] The above effects or activities can be detected by any method or technique known in the art. For example, excitatory synaptic transmission can be measured by the excitatory postsynaptic potentials (SC-CA1 fEPSPs) in the Scheffer collateral-CA1 area. When the upward slope of SC-CA1 fEPSPs increases, it indicates that an antidepressant-like effect has been produced. GluA1 is an important subunit of the ionotropic glutamate receptor (AMPAR), and its function is closely related to the antidepressant-like effect. Depressive-like behavior can be measured by the forced swimming test (FST), which measures the immobility time of mice to assess the degree of behavioral despair; the sugar preference test (SPT), which assesses the degree of anhedonia by the proportion of sugar consumed; and the three-compartment social test, which tests the mice's preference for new social objects and social behavior.
[0166] The agonists of the present invention are particularly suitable for administration to subjects whose abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes is lower than that of normal controls, which can be measured by detecting the binding level of μ-opioid receptor ligands.
[0167] Pharmaceutical Composition
[0168] In this invention, a pharmaceutical composition comprising the μ-δ opioid receptor heterodimer agonist of the present invention is also provided for the treatment and / or relief of depression-like disorders.
[0169] The pharmaceutical composition of the present invention comprises: a therapeutically effective amount of a μ-δ opioid receptor heterodimer agonist as a first active ingredient, and a pharmaceutically acceptable carrier. Furthermore, the pharmaceutical composition of the present invention may also comprise: a second active ingredient, wherein the second active ingredient is another active substance with antidepressant-like activity, such as SSRIs and SNRIs.
[0170] As used herein, the term "effective amount" or "effective dose" refers to an amount that is functional or active in humans and / or animals and is acceptable to them. It refers to the amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or that exhibits a detectable therapeutic or preventative effect. Therapeutic effects also include a reduction in physiological symptoms. The precise effective amount for a given subject depends on the subject's body size and health status, the nature and severity of the condition, and the choice of the therapeutic agent and / or combination of therapeutic agents administered. For a given condition, the effective amount can be determined using routine laboratory methods.
[0171] The effective amount of a pharmaceutical composition can vary depending on the mode of administration and the severity of the disease to be treated. A preferred effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the drug, such as tissue distribution, bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration.
[0172] As used herein, pharmaceutically acceptable carriers include, but are not limited to: solvents, dispersion media, coatings, antibacterial or antifungal agents, isotonic agents and absorption delay agents, buffered saline, physiological saline, phosphate buffer, citrate buffer, acetate buffer, bicarbonate buffer, sucrose solution, salt solution, polysorbate solution, or combinations thereof. In a preferred embodiment, the pharmaceutically acceptable carrier is a delivery carrier, including but not limited to liposomes, nanoparticles, etc.
[0173] The pharmaceutical compositions of the present invention can be in any form or dosage form, including but not limited to: injections, tablets, powders, granules, capsules, lyophilized preparations, solutions, and syrups. In a preferred embodiment, the dosage form of the pharmaceutical composition is preferably an injection.
[0174] Therapeutic applications
[0175] This invention also provides the application of the μ-δ opioid receptor heterodimer agonist of this invention for the treatment of depression-like related disorders. As used herein, the term "depression-like related disorder" includes depression-related disorders, anxiety-related disorders, and / or pain-related disorders. In a preferred embodiment, the disorder specifically includes depression, anxiety disorder, pain, or a combination thereof. In a preferred embodiment, the depression includes major depressive disorder and treatment-resistant depression.
[0176] In this invention, the subjects of treatment include mammals, such as humans, non-human primates, rodents (such as mice and rats), etc.
[0177] In this invention, the subjects of treatment are preferably subjects with the following subtype characteristics: subjects whose abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes are lower than those of normal controls. Normal controls are healthy individuals of the same species as the subjects who do not suffer from depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0178] In a preferred embodiment, the abundance A1 of μ-δ opioid receptor heterodimers in the astrocytes of the preferred subject is A1 / A0 ≤ 0.8, more preferably ≤ 0.5, and more preferably ≤ 0.3, compared to the abundance A0 of μ-δ opioid receptor heterodimers in the astrocytes of the normal control; or the activity B1 of μ-δ opioid receptor heterodimers in the astrocytes of the preferred subject is B1 / B0 ≤ 0.8, more preferably ≤ 0.5, and more preferably ≤ 0.3, compared to the activity B0 of μ-δ opioid receptor heterodimers in the astrocytes of the normal control.
[0179] Drug screening methods
[0180] In this invention, a method is also provided for screening or identifying potential therapeutic agents for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0181] In one implementation, the potential antidepressant-like activity of the test substance is determined by detecting the effect of the test substance on the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in astrocytes.
[0182] Specifically, for the test group, the test substance was added to the astrocyte culture system, and the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the cells of the test group were observed; in the control group, the test compound was not added to the same cell culture system, and the abundance (A0) and / or activity (B0) of μ-δ opioid receptor heterodimers in the cells of the control group were observed; wherein, if the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the cells of the test group were significantly higher than those in the control group, it indicates that the test substance is a potential therapeutic agent for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
[0183] In one implementation, the potential antidepressant-like activity of the test compound is determined by detecting or predicting the binding of the test compound to the μ-δ opioid receptor heterodimer.
[0184] The specific steps include providing a test compound, predicting or detecting whether the test compound binds to a μ-δ opioid receptor heterodimer; if the test compound binds to the μ-δ opioid receptor heterodimer, it indicates that the test compound is a candidate compound for treating depression-related, anxiety-related, and / or pain-related disorders or conditions. Specifically, the prediction or detection involves whether the test compound binds to a key site of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, said key site including: D147, Y148, V300, or combinations thereof. The prediction can be performed using computational simulation tools or software that are readily available to those skilled in the art.
[0185] In a preferred embodiment, the drug screening method further includes administering the candidate substance to disease model animals to further test the therapeutic activity of the substance. The disease model animals are animals associated with depression, anxiety, and / or pain, such as the chronic unpredictable mild stress (CUMS) mouse model.
[0186] The beneficial effects of this invention include:
[0187] 1. This invention reveals for the first time the structure, binding site, and mechanism by which the μ-δ opioid receptor heterodimer plays a role in antidepressant-like effects, thus providing novel antidepressant-like methods and ideas.
[0188] 2. This invention provides the use of μ-δ opioid receptor heterodimer activators in antidepressant-like effects, which can be used to treat depression-related, anxiety-related, and pain-related diseases.
[0189] 3. The μ-δ opioid receptor heterodimer activator of the present invention has a rapid onset of action, is not easily addictive, and has high safety.
[0190] 4. The drug screening method of the present invention can be used to screen novel, safe, and effective next-generation antidepressants.
[0191] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and fractions are weight percentages and weight fractions.
[0192] Example 1: The antidepressant mechanism of ketamine and HNK
[0193] (I) Ketamine and HNK have different mechanisms of action.
[0194] HNK and ketamine can enhance excitatory synaptic transmission in multiple brain regions, but their specific antidepressant mechanisms remain unclear. In this study, the effects of HNK and ketamine on excitatory synaptic transmission in the hippocampus were compared. The methods are as follows:
[0195] Acute hippocampal slices were prepared using adult C57BL / 6J mice. The Scheffer collaterals were then electrically stimulated.
[0196] (Schaffer collateral, SC) was used to record excitatory postsynaptic field potentials (SC-CA1 fEPSPs) in the radiative layer of the CA1 region of the hippocampus. Ketamine and HNK were added to the perfusion fluid, respectively, and their effects on the rise slope of fEPSPs were observed. After ketamine treatment stabilized, HNK was added further to detect the additive effect. The NMDA receptor antagonist MK-801 was used as a control, and the additional effect of HNK in the presence of MK-801 was also detected.
[0197] The results showed that the addition of ketamine (10 μM) and HNK (10 μM) to the perfusion fluid increased the upward slope of SC-CA1 fEPSPs by 62.1 ± 2.1% and 61.9 ± 5.9%, respectively (p = 0.09 for ketamine versus HNK).
[0198] After the enhancing effect of ketamine reached a stable state, the addition of HNK to the bath solution further increased the slope of SC-CA1fEPSPs by 63.1 ± 6.3% (comparison between the HNK plus ketamine group and the ketamine group, p < 0.0001) (Figure 1A). Conversely, increasing the ketamine concentration to 30 μM did not cause a further enhancement of SC-CA1fEPSPs (comparison between the 30 μM ketamine group and the 10 μM ketamine group, p = 0.13) (Figure 1B).
[0199] MK-801 (10 μM), a selective non-competitive NMDA receptor antagonist, increased the slope of SC-CA1 fEPSPs by 95.6 ± 3.8%, while HNK perfusion further enhanced SC-CA1 fEPSPs, reaching 153.7 ± 3.0% under the action of MK-801 (comparison between HNK plus MK-801 group and MK-801 group, p < 0.0001) (Figure 1C).
[0200] The above results indicate that ketamine and HNK enhance SC-CA1 fEPSPs through different signaling pathways, and that the effect of HNK in enhancing excitatory synaptic transmission is independent of blocking NMDA receptors.
[0201] (II) The role of MOR in the antidepressant mechanism of ketamine or HNK
[0202] To investigate whether the opioid system is involved in ketamine- or HNK-induced enhancement of hippocampal excitatory synaptic transmission, the effects of selective agonists or antagonists of MOR on SC-CA1 fEPSPs were tested.
[0203] The effects of (2R,6R)-HNK and ketamine on fEPSPs were observed in the presence of DAMGO (1 μM), a selective agonist of MOR, and CTOP (1 μM), a selective antagonist of MOR.
[0204] The results showed that DAMGO mimicked and blocked the (2R,6R)-HNK-induced enhancement of SC-CA1 fEPSPs, while ketamine further enhanced SC-CA1 fEPSPs on the basis of DAMGO (Figures 1D and G). Furthermore, the selective antagonist of MOR, CTOP (1 μM), weakened the upward slope of SC-CA1 fEPSPs and completely eliminated the effect of (2R,6R)-HNK on SC-CA1 fEPSPs, but had no effect on the effect of ketamine (Figures 1E and H).
[0205] Subsequently, to understand the signaling pathway by which ketamine induces MOR-independent activation of SC-CA1 fEPSPs, the effect of the NMDA receptor antagonist APV on the action of ketamine was observed. The results showed that pre-incubation with APV (50 μM) completely blocked the action of ketamine in Figure 1E (Figures 1F and I).
[0206] These results indicate that activation of MOR-containing opioid receptors is essential for (2R,6R)-HNK-induced enhancement of hippocampal excitatory synaptic transmission, and that ketamine enhances SC-CA1 fEPSPs by blocking NMDA receptors. This suggests that (2R,6R)-HNK functions in a manner dependent on MOR activation, while ketamine's effects are independent of MOR, acting instead through blocking NMDA receptors.
[0207] Example 2: The effect of MOR activation or blockade on the (2R,6R)-HNK antidepressant-like effect
[0208] In this embodiment, the effect of MOR activation or blockade on the (2R,6R)-HNK antidepressant-like effect was further examined through mouse behavioral experiments.
[0209] Behavioral experiments included: the forced swimming test (FST), which measured the time mice remained still and assessed the degree of behavioral despair; the sugar preference test (SPT), which assessed the degree of anhedonia by the proportion of sugar water consumed; and the three-compartment social test, which tested the mice's preference for new social objects and their social behavior.
[0210] (I) Effects of MOR agonists or antagonists on the antidepressant-like effects of (2R,6R)-HNK
[0211] The effects of (2R,6R)-HNK on mouse behavior were tested in the presence of the MOR agonist DAMGO (1 μM) or the antagonist CTOP (1 μM).
[0212] The results showed that in the forced swimming experiment and the sucrose preference experiment, DAMGO simulated and masked the effects of (2R,6R)-HNK-induced reduction in immobility time in the forced swimming experiment and increased sucrose preference in the sucrose preference experiment, while CTOP completely reversed the effects of (2R,6R)-HNK in both experiments (Figures 2A and 2B).
[0213] In the three-compartment social experiment, (2R,6R)-HNK enhanced the social behavior and preference for new social objects in the test mice. These effects could be mimicked and masked by DAMGO and blocked by CTOP (Figure 2C).
[0214] (II) Detection of the antidepressant-like effect of (2R,6R)-HNK on MOR gene knockout mice
[0215] To test the necessity of MOR for the antidepressant-like effect of (2R,6R)-HNK, MOR was knocked out using CRISPR / Cas9 technology. The results showed that MOR knockout mice (MOR-KO) exhibited increased immobility time in the forced swimming test and decreased water consumption in the sucrose preference test, demonstrating depressive-like behavior. Furthermore, administration of (2R,6R)-HNK did not produce an antidepressant-like effect, indicating that MOR knockout completely blocked the antidepressant-like effect of (2R,6R)-HNK in these two experiments (Figures 2D and E, F and G).
[0216] (III) Cellular localization of MOR involved in the (2R,6R)-HNK antidepressant-like effect
[0217] Reports indicate that MOR is located in the cell body, dendrites, axons, and axon terminals of GABAergic inhibitory neurons, including interneurons expressing parvalbumin (PV); in addition, MOR is highly expressed in hippocampal astrocytes.
[0218] To elucidate the cellular localization of MOR involved in the (2R,6R)-HNK antidepressant-like effect, mice with MOR specifically knocked out in PV interneurons (OPRM1) were constructed. PV -cKO), and mice that specifically knock out MOR in astrocytes (OPRM1) GFAP -cKO), and adopt OPRM1 flox / floxMice were used as a control.
[0219] The results showed that (2R,6R)-HNK in OPRM1 PV -cKO mice showed a significant reduction in immobility time during forced swimming and an increased preference for sucrose, compared to OPRM1 mice. flox / flox The same effect was observed in mice; furthermore, (2R,6R)-HNK was observed in OPRM1. PV The enhancement of SC-CA1 fEPSPs and the increase of GluA1 in -cKO mice were also associated with the increase in OPRM1. flox / flox Similar in mice.
[0220] However, in mice with MOR specifically knocked out in astrocytes (OPRM1) GFAP In the (2R,6R)-HNK assay, (2R,6R)-HNK failed to induce an antidepressant-like effect in the forced swimming test and the sucrose preference test (Figures 2H and I).
[0221] The above results indicate that the antidepressant-like effect of (2R,6R)-HNK requires activation of opioid receptors containing MOR in astrocytes.
[0222] (iv) The role of DOR in the antidepressant-like effect of (2R,6R)-HNK
[0223] Delta opioid receptors (DORs) are involved in pain regulation, pleasure response, and mood control. DORs are primarily located in GABAergic interneurons and astrocytes. To investigate whether DORs are involved in the antidepressant-like effects of (2R,6R)-HNK, in this embodiment, mice with DORs specifically knocked out in astrocytes (OPRD1) were constructed. GFAP -cKO) or mice with DOR specifically knocked out in PV interneurons (OPRD1) pv -cKO), and use OPRD1 flox / flox Mice were used as a control.
[0224] The results showed that knocking out DOR(OPRD1) in astrocytes GFAP (-cKO) eliminated the antidepressant-like effect of (2R,6R)-HNK in the forced swimming and sucrose preference tests, while (2R,6R)-HNK significantly increased OPRD1. flox / flox Mice showed a preference for sucrose and reduced immobility time (Fig. 2L and M). Furthermore, (2R,6R)-HNK enhanced OPRD1. flox / flox SC-CA1fEPSPs in mouse hippocampal slices increased GluA1 levels, but had little effect on OPRD1. GFAP -cKO mice did not exhibit this effect (Figure 2L and M).
[0225] Consistent with the above results, the (2R,6R)-HNK-induced enhancement of SC-CA1 fEPSPs and increase of GluA1 can be eliminated by the DOR antagonist ICI174684 (1 μM) and can be mimicked by the DOR agonist DPDPE (1 μM).
[0226] In addition, specific knockout of the δ opioid receptor (OPRD1) in PV interneurons pv (-cKO) failed to eliminate the antidepressant-like effects of (2R,6R)-HNK in the forced swimming and sucrose preference tests. Furthermore, it did not attenuate the enhancing effects of (2R,6R)-HNK on SC-CA1-fEPSCs and the increasing effects on GluA1.
[0227] These results suggest that the antidepressant-like effects of (2R,6R)-HNK require activation of DOR-containing opioid receptors expressed on astrocytes.
[0228] Consistent with the above results, incubation with (2R,6R)-HNK for 2 hours increased the levels of brain-derived neurotrophic factor (BDNF) and GluA1 in hippocampal neuron-glial cell co-culture and pure astrocyte culture, but had no effect in isolated hippocampal neuron culture (Fig. 2P and Q). In immunofluorescence staining experiments, (2R,6R)-HNK treatment for 2 hours increased the quantity and size of GluA1 on proximal dendrites of neurons in neuron-glial cell co-culture, but had no effect in isolated neuron culture (Fig. 2R and S).
[0229] Example 3: The antidepressant-like effect of (2R,6R)-HNK requires activation of the MOR-DOR heteromer (I) Mechanism of MOR or DOR in antidepressant effect
[0230] The results of Examples 1 and 2 show that activation of either MOR or DOR can mimic the antidepressant effect of (2R,6R)-HNK, while MOR or DOR antagonists can block this effect. In this example, their mechanism of action was further investigated.
[0231] First, we investigated whether (2R,6R)-HNK activates MOR and DOR by promoting the release of endogenous opioids. Using a rat β-endorphin (β-EP) ELISA kit (Jianglai Biotechnology, Shanghai), we measured the release of endogenous β-endorphin. We found that injection of (2R,6R)-HNK did not increase the concentration of β-endorphin in either the hippocampus or the prefrontal cortex. This indicates that (2R,6R)-HNK does not activate MOR and DOR by promoting the release of endogenous opioids.
[0232] Secondly, the existing forms of opioid receptors during action were examined. Opioid receptors can exist in both homomeric and heteromeric forms (e.g., MOR-MOR homomers, DOR-DOR homomers) and heteromer forms (MOR-DOR heteromers). The antidepressant effect of (2R,6R)-HNK was investigated to determine whether it depends on MOR-DOR heteromer activation.
[0233] The results showed that DAMGO (MOR agonist) in OPRD1 GFAP -cKO mice did not enhance fEPSPs (Figure 3A). DPDPE (DOR agonist) in OPRM1 GFAP The effect was weakened in -cKO mice (Figure 3B). This indicates that DAMGO / DPDPE mainly activates the MOR-DOR heteromer rather than the homomer at the experimental concentration.
[0234] (II) The role of DOR-MOR heterodimer in the (2R,6R)-HNK antidepressant-like effect
[0235] Next, to investigate the role of DOR-MOR heterodimer in the (2R,6R)-HNK antidepressant-like effect, the DOR-MOR heterodimer agonist CYM51010 and the DOR-MOR heterodimer disruptor peptide (PEP) were used.
[0236] The results showed that the DOR-MOR heterodimer agonist CYM51010 mimicked and blocked the effect of (2R,6R)-HNK on SC-CA1 fEPSPs, while the DOR-MOR heterodimer disruptor peptide (PEP) completely eliminated the effect of (2R,6R)-HNK (Figures 3C and D). Furthermore, CYM51010 mimicked and blocked the effect of (2R,6R)-HNK in increasing GluA1 abundance in freshly prepared hippocampal slices, while PEP eliminated this effect (Figures 3E and F).
[0237] Furthermore, mice treated with corticosteroids for 3 weeks exhibited lower sociality and preference for new social objects in the three-compartment social interaction test, and increased immobility time in the tail suspension test and forced swimming test. Injection of (2R,6R)-HNK 24 hours later reversed the effects of chronic corticosteroids in these tests, and the effects of (2R,6R)-HNK could be mimicked and blocked by CYM51010 pretreatment, but were blocked by PEP (Figure 3G-J).
[0238] The above results indicate that activation of the MOR-DOR heteromer is involved in the antidepressant-like response of (2R,6R)-HNK.
[0239] Example 4: Regulation mechanism of (2R,6R)-HNK on MOR-DOR
[0240] In this embodiment, the effects of chronic stress and (2R,6R)-HNK on the abundance of MOR-DOR heteromers were investigated.
[0241] In immunofluorescence staining experiments, it was observed that the abundance of DOR-MOR heterodimer expressed on GFAP-positive cells (astrocytes) in the CA1 region of the hippocampus was reduced in mice subjected to 3 weeks of chronic stress, and was restored by (2R,6R)-HNK treatment for 24 hours (Fig. 4A and B).
[0242] The dynamic and conformational changes of MOR and DOR monomers were tracked using MINFLUX technology to detect the formation distance between MOR and DOR, with 24 nm considered the maximum distance for the two monomers to form functional heterodimers. Specifically, in Chinese hamster ovary (CHO) cells co-transfected with MOR-EGFP and DOR-ALFA, MINFLUX nanomicroscopy revealed a significant increase in the probability of MOR and DOR forming heteromers with a distance of less than 24 nm after 1 hour of stimulation with (2R,6R)-HNK or CYM51010 (Figs. 4C and E). Furthermore, this effect of (2R,6R)-HNK or CYM51010 could be completely reversed by PEP (Figs. 4D and F).
[0243] Previous studies have shown that the MOR-DOR heteromer constitutively binds to β-arrestin to promote the activation of extracellular signal-regulated kinase 1 / 2 (ERK1 / 2). To investigate the effect of (2R,6R)-HNK on cellular signaling of the MOR-DOR heteromer, (2R,6R)-HNK was applied to HEK-293 cells transfected with either MOR or DOR, or cells simultaneously transfected with both plasmids. The results showed that (2R,6R)-HNK stimulation specifically increased the abundance of flag-labeled DOR-associated β-arrestin in cells simultaneously transfected with both MOR and DOR, but this effect was not observed in cells transfected with only MOR or DOR (Figures 4G and H).
[0244] Next, the stability of the μ and δ opioid receptor heterodimers predicted by AlphaFold3 was evaluated using 400 ns atomic and molecular dynamics (MD) simulations to determine whether (2R,6R)-HNK binds directly to the MOR-DOR heteromer. The transmembrane heterodimer composed of μ and δ opioid receptors exhibited a stable conformation with minimal fluctuations. The root mean square deviation (RMSD) of the entire complex and each individual receptor remained below 0.5 nm. Despite significant sequence and structural homology between μ and δ opioid receptors, (2R,6R)-HNK binds only to the μ opioid receptor in the heterodimer. This selective binding is attributed to the N-terminal domain of the μ opioid receptor in the heterodimer complex blocking the binding pocket of the δ opioid receptor. Furthermore, combined free energy analysis showed that the binding of (2R,6R)-HNK to the μ-opioid receptor mainly involves salt bridge interaction with aspartate 147 (D147) and π-π stacking interaction with tyrosine 148 (Y148) (Figure 4I-K).
[0245] Example 5: (2R,6R)-HNK restores extracellular glutamate homeostasis by upregulating GLT-1 expression levels in astrocytes.
[0246] This study found that the levels of astrocyte markers GFAP, glutamate transporter GLT-1, and GLAST proteins were significantly reduced in the prefrontal cortex (PFC) of ACTH (adult male mice injected daily with the stress hormone adrenocorticotropic hormone for two consecutive weeks) mice and CUMS mice, while HNK rapidly restored their expression. Brain microdialysis experiments showed that HNK reduced extracellular glutamate concentration in PFC cells (Figure 5A) and decreased resting-state NMDA receptor (NMDAR) activation by enhancing GLT-1-mediated glutamate uptake (Figures 5B-C). Notably, HNK had no acute effect on NMDAR currents in isolated neurons, suggesting that its effect is not direct on NMDAR but rather indirectly achieved through the regulation of astrocyte function. shRNA-mediated GLT-1 knockdown (KD) completely blocked the ameliorative effects of HNK on synaptic transmission, BDNF / eEF2 pathway and behavior (Figure 5F-I), confirming that GLT-1 upregulation is a necessary mechanism for the antidepressant effect of HNK (Figure 5J).
[0247] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.
Claims
1. Use of a μ-δ opioid receptor heterodimer or an agonist thereof, characterized in that, This is used to prepare a pharmaceutical composition for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
2. The use as described in claim 1, characterized in that, The μ-δ opioid receptor heterodimer is the μ-δ opioid receptor heterodimer in astrocytes.
3. The use as described in claim 1, characterized in that, The μ-δ opioid receptor heterodimer agonist is used to increase the abundance and / or activity of μ-δ opioid receptor heterodimers.
4. The use as described in claim 1, characterized in that, The agonist is selected from the group consisting of small molecule compounds, proteins, nucleic acids, or combinations thereof.
5. The use as described in claim 1, characterized in that, The agonist binds to key sites of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, including D147, Y148, V300, or combinations thereof (numbered based on the sequence of the mouse μ-opioid receptor).
6. The use as described in claim 1, characterized in that, The agonists include: (2R,6R)-hydroxydemethylketamine (HNK) and CYM51010.
7. The use as described in claim 1, characterized in that, The agonist has one or more activities selected from the group consisting of: (1) Enhances excitatory synaptic transmission in subjects; (2) Increase the amount of GluA1 in the subjects; (3) Upregulates GLT-1 expression levels in astrocytes; (4) Improved behavioral despair in subjects; (5) Improves the subject's lack of pleasure.
8. The use as described in claim 1, characterized in that, The disorders or conditions mentioned include: depression, anxiety, pain, or a combination thereof.
9. The use as described in claim 1, characterized in that, The pharmaceutical composition is administered to subjects with the following subtypes: subjects whose abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes are lower than those of normal controls.
10. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises: (i) A therapeutically effective dose of a μ-δ opioid receptor heterodimer agonist; and (ii) Pharmaceutically acceptable carriers.
11. A medicine box, characterized in that, The medicine box includes: (a) a first pharmaceutical composition, said first pharmaceutical composition comprising (a1) a μ-δ opioid receptor heterodimer agonist; and (a2) a pharmaceutically acceptable carrier; and (b) A second pharmaceutical composition comprising (b1) another medicine for treating depression-related, anxiety-related, and / or pain-related disorders or conditions; and (a2) a pharmaceutically acceptable carrier.
12. A reagent kit, characterized in that, The kit includes: (Y1) Detection reagent, wherein the detection reagent is a reagent for detecting the abundance and / or activity of μ-δ opioid receptor heterodimers; and (Y2)μ-δ opioid receptor heterodimer agonist.
13. The kit according to claim 12, characterized in that, The kit also includes a label and / or instructions; the label and / or instructions describe the method of administration of the kit: using the (Y1) assay reagent to detect whether the abundance and / or activity of μ-δ opioid receptor heterodimer in the subject is lower than that in the normal control; if so, administering the (Y2) μ-δ opioid receptor heterodimer agonist to the subject.
14. A method for screening or identifying potential therapeutic agents for treating depression-related, anxiety-related, and / or pain-related disorders or conditions, characterized in that, The method includes the following steps: (S1) In the test group, the test substance was added to the cell culture system, and the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the cells of the test group were observed; in the control group, the test compound was not added to the same cell culture system, and the abundance (A0) and / or activity (B0) of μ-δ opioid receptor heterodimers in the cells of the control group were observed. If the abundance (A1) and / or activity (B1) of μ-δ opioid receptor heterodimers in the test group are significantly higher than those in the control group, it indicates that the test substance is a potential therapeutic agent for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
15. The method as described in claim 14, characterized in that, The cells include astrocytes.
16. A method for screening or identifying small molecule compounds for treating depression-related, anxiety-related, and / or pain-related disorders or conditions, characterized in that, The method includes the following steps: (Z1) Provides a test compound and predicts or detects whether the test compound binds to a μ-δ opioid receptor heterodimer; if the test compound binds to a μ-δ opioid receptor heterodimer, it indicates that the test compound is a candidate compound for treating depression-related, anxiety-related, and / or pain-related disorders or conditions.
17. Use of a small molecule compound in the preparation of an agonist for increasing the abundance and / or activity of μ-δ opioid receptor heterodimers, characterized in that, The small molecule compound binds to key sites of the μ-opioid receptor in the μ-δ opioid receptor heterodimer, including: D147, Y148, V300, or combinations thereof (numbered based on the sequence of the mouse μ-opioid receptor).
18. A method for treating depression-related, anxiety-related, and / or pain-related disorders or conditions, characterized in that, The method includes administering a μ-δ opioid receptor heterodimer agonist to a subject in need.
19. The method as described in claim 18, characterized in that, The subjects were those with the following subtype characteristics: subjects whose abundance and / or activity of μ-δ opioid receptor heterodimers in astrocytes were lower than those of normal controls.
